Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

eat_dis_watermelon

Author hasn't set their bio yet

Published

19 Sep 25

Updated

21 Nov 25

Views

Not Invested

Shared on 21 Nov 25

GLP-1 drugs part of medicare

A push to include these weight-loss drugs in Medicare could make them easier for more people to get, which may keep demand strong. Recent results also suggest growth is coming from more prescriptions rather than price hikes, with no clear signs demand is cooling.

115 views

Fair Value vs Share Price

US$1.19k

vs US$1.18k0.8% undervalued

20%

Revenue growth

25.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Eli Lilly

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with proven track record.

Market capUS$1.0t

PB33.7x

Estimated Growth12.4%

Dividend Yield0.6%

Full analysis

CEO & management

David Ricks

CEO

6.8yrs

CEO Tenure

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.